Bone Biomarker Identified for Metastatic Prostate Cancer

TON - MARCH 2012 VOL 5, NO 2 published on April 10, 2012 in In the News
Alice Goodman

A new quantitative imaging bone biomarker has been identified that can assess response and is prognostic for survival in men with metastatic castration-resistant prostate cancer (mCRPC). 

Called the bone scintigraphy index (BSI), it represents the first quantitative imaging biomarker in prostate cancer. In a head-to-head comparison, the BSI was superior to PSA (prostate-specific antigen)—the traditional method—in assessing response to therapy and prognosticating for survival after 3 and 6 months on therapy for mCRPC, according to a study published online ahead of print in the Journal of Clinical Oncology on January 9, 2012. Michael Morris, MD, Memorial Sloan-Kettering Cancer Center, New York City, was senior author of the paper.

Bone scintigraphy is an older technology that images bone but not the cancerous lesions themselves. It shows the effect on the bone surrounding the metastasis, and, as such, is considered an imperfect tool on its own. 

BSI is a method of expressing the tumor burden in bone as a percent of the total skeletal mass based on reference man skeletal masses. The study included 88 men enrolled in 4 different clinical trials who had bone scintigraphy done at baseline, 3 months, and 6 months on therapy

The percent change in BSI from baseline to 3 and 6 months was prognostic for survival. Doubling of the BSI was associated with an almost 2-fold increase in risk of death. When compared head-to-head with PSA, change in PSA from baseline was not prognostic for survival.

“BSI tells us about response to therapy and survival. When the BSI goes up, survival is shorter, and when it goes down, survival will be longer,” Morris explained. He and his colleagues are developing a computer-generated BSI that will have wide applicability. At present, the BSI is computed manually. 

Related Items
First Chemoimmunotherapy Regimen Granted Accelerated Approval for Patients with Previously Treated DLBCL
Yvette Florio Lane
Web Exclusives published on June 12, 2019 in FDA Approvals, News & Updates, In the News
FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer
Web Exclusives published on May 14, 2019 in Breast Cancer, FDA Approvals, News & Updates, In the News
Tibsovo Now FDA Approved as First-Line Treatment for AML with IDH1 Mutation
Web Exclusives published on May 7, 2019 in FDA Approvals, News & Updates, In the News
FDA Approves Pembrolizumab plus Axitinib for Advanced Renal-Cell Carcinoma
Web Exclusives published on April 23, 2019 in FDA Approvals, News & Updates, In the News, Renal-Cell Carcinoma
April 16, 2019 – FDA Approvals, News & Updates
Web Exclusives published on April 16, 2019 in FDA Approvals, News & Updates, In the News, Lung Cancer
FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer
Web Exclusives published on April 5, 2019 in Breast Cancer, FDA Approvals, News & Updates, In the News
Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness
Web Exclusives published on April 1, 2019 in Breast Cancer, FDA Approvals, News & Updates, In the News
FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Web Exclusives published on March 22, 2019 in FDA Approvals, News & Updates, In the News, Lung Cancer
FDA Approves Tecentriq plus Abraxane—First Immunotherapy for PD-L1– Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Web Exclusives published on March 15, 2019 in FDA Approvals, News & Updates, In the News
March 08, 2019 – FDA Approvals, News & Updates
Web Exclusives published on March 8, 2019 in FDA Approvals, News & Updates, In the News
Last modified: May 21, 2015